摘要
目的探析丙种球蛋白联合他克莫司治疗重症肌无力(MG)的临床效果及安全性。方法选取2019年12月—2020年12月阜新市某医院诊治的80例MG患者为研究对象,采用计算机随机分组法分为研究组和对照组,每组40例。对照组患者采用他克莫司治疗,研究组患者在对照组治疗基础上联用丙种球蛋白治疗,2组患者均持续治疗30 d。比较2组患者不良反应发生情况,比较2组患者治疗前后重症肌无力定量评分表(QMG)评分,免疫生化指标[肿瘤坏死因子-α(TNF-α)、雌二醇(E_(2))]水平变化情况。结果治疗前,2组患者QMG评分,TNF-α及E_(2)水平比较,差异均无统计学意义(P>0.05)。治疗后,2组患者QMG评分,TNF-α及E_(2)水平均低于治疗前,且研究组低于对照组,差异均有统计学意义(P<0.001)。研究组患者的不良反应发生率为10.00%,高于对照组的7.50%,但差异无统计学意义(P>0.05)。结论丙种球蛋白联合他克莫司治疗可明显改善MG患者的肌无力严重程度及免疫功能,且安全性较高,可进一步推广应用。
Objective To explore the clinical effect and safety of gammaglobulin combined with tacrolimus in the treatment of myasthenia gravis(MG).Methods Eighty cases of MG patients treated in a hospital in Fuxin city from December 2019 to December 2020 were selected for the stud and divided into a study group and a control group using the computerized random grouping method,with 40 cases in each group.The patients in the control group were treated with tacrolimus,and the patients in the study group were treated with gammaglobulin on top of the control group,and both groups were treated for 30 d.The incidence of adverse reactions in the two groups was compared,and the quantitative myasthenia gravis(QMG)test scores,changes in immunobiochemical indexes[tumor necrosis factor-α(TNF-α),estradiol(E_(2))]levels before and after treatment were compared between the two groups.Results Before treatment,there was no statistically significant difference in QMG score,TNF-αand E_(2) levels between the 2 groups(P>0.05).After treatment,the QMG scores,TNF-αand E_(2) levels were lower in both groups than before treatment,lower in the study group than in the control group,and the differences were statistically significant(P<0.001).The incidence of adverse reactions in patients in the study group was 10.00%,which was higher than that in the control group(7.50%),but the difference was not statistically significant(P>0.05).Conclusion Gammaglobulin combined with tacrolimus therapy can significantly improve the severity of myasthenia gravis and immune function in MG patients with a high safety profile,and it may be further promoted.
作者
任巍巍
冯显
于波
Ren Weiwei;Feng Xian;Yu Bo(Department of Neurology, Fuxin Central Hospital, Fuxin Liaoning 123000, China)
出处
《保健医学研究与实践》
2022年第1期46-48,共3页
Health Medicine Research and Practice
